ASH 2017 | The future for the treatment of Hodgkin lymphoma
Stephen Ansell
• 11 Dec 2017
The treatment in Hodgkin lymphoma has benefited greatly with the advances in new therapies such as the PD1 immune checkpoint blockade. Agents such as nivolumab and pembrolizumab, anti-PD1 antibodies, have very high response rates in Hodgkin lymphoma.
Stephen Ansell, MD, PhD, of the Mayo Clinic, Rochester, MN, talks about moving forward on the successful treatments for Hodgkin lymphoma. One future approach has been seen with the trial of AMF13 plus pembrolizumab. Dr Ansell speaks about the promising results which have shown high response rates and a high safety profile, hinting at an exciting future approach.
